



Biotech Daily

Monday March 14, 2011

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: LBT UP 8%; BENITEC DOWN 10%**
- * **PHOSPHAGENICS PLACEMENT TO RAISE \$5.6m FOR OXYCODONE PATCH**
- * **SILENT RESTART FOR NARHEX**
- * **PHARMAUST EGM TO RATIFY PLACEMENT ISSUE**
- * **GENESIS APPOINTS DANIEL MAHNERT-LUEG, GRAHAM CHIN DIRECTORS**

MARKET REPORT

The Australian stock market fell 0.4 percent on Monday March 14, 2011, the Labour Day public holiday in Victoria, with the S&P ASX 200 down 18.4 points to 4626.4 points.

Seven of the Biotech Daily Top 40 stocks were up, 20 fell, seven traded unchanged and five were untraded.

LBT was best, up half a cent or 7.6 percent to 7.1 cents, with 178,492 shares traded, followed by Prana up 7.4 percent to 14.5 cents with 19,000 shares traded.

Circadian climbed 5.3 percent; Virax was up 3.45 percent; Sirtex was up 1.7 percent; with Cochlear, Impedimed and Starpharma up less than one percent.

Benitec led the falls, down 0.3 cents or 10.3 percent to 2.6 cents, with 2.7 million shares traded, followed by Phosphagenics down 8.7 percent to 10.5 cents with 1.7 million shares traded.

Bioniche and Chemgenex lost more than seven percent; Living Cell fell 6.6 percent; Phylogica and QRX fell more than five percent; Cellestis fell 4.2 percent; Biota, Genetic Technologies and Nanosonics were down more than three percent; Bionomics, Clinuvel, Prima and Viralytics shed more than two percent; with Acrux, Alchemia, Pharmaxis, Resmed, Tissue Therapies and Universal Biosensors down more than one percent.

PHOSPHAGENICS

Phosphagenics says it has commitments to raise \$5.6 million through the placement of 62,220,000 shares at nine cents each.

Phosphagenics said the proceeds would be used to fund clinical trials of its “core development product – the world’s first oxycodone pain relief patch” with phase II trials expected to begin this year.

The company said the funds would also assist the roll-out of its cosmetic products including the “anti-cellulite cream”, using AOD9604 licenced from Calzada.

The company said that Lodge Partners arranged and managed the placement to institutions along with professional and sophisticated investors.

Phosphagenics fell one cent or 8.7 percent to 10.7 cents with 1.7 million shares traded.

NARHEX LIFE SCIENCES

Narhex returned to ASX trading today, but no shares changed hands.

The company had four bids for a total of 5,500,000 shares at 1.5 cents and just one seller wanting three cents for his or her 500,000 shares.

Three buyers were offering 1.4 cents a share and two were offering 1.2 cents a share.

Prior to its suspension Narhex traded at 1.6 cents.

PHARMAUST

Pharmaust shareholders will vote to ratify the allotment and issue of 38,206,250 placement shares.

Pharmaust said the shares were placed at 1.6 cents each to sophisticated, institutional and other investors and raised \$611,300.

The meeting will be held at RSM Bird Cameron, 8 St Georges Terrace, Perth on April 15, 2011 at 12pm (AWST).

Pharmaust was untraded at 2.9 cents.

GENESIS RESEARCH AND DEVELOPMENT CORP

Genesis says Daniel Mahnert-Lueg and Graham Chin have been appointed as directors and that Dr Stewart Washer has resigned.

Genesis said Mr Mahnert-Lueg was a German national, based in Shanghai with experience in marketing and investment.

The company said Mr Mahnert-Lueg held a Bachelor of Science degree and a Masters of Business Administration.

Genesis said Mr Chin had more than 20 years experience in the banking and finance industry in New Zealand and was formerly the director of wealth management at UBS AG, Singapore and head of Asian banking for the National Bank of New Zealand.

The company said that previously Mr Chin was a director of Natural Dairy (NZ) Holdings, Genesis said held a post-graduate diploma in banking.

The company said Dr Stewart Washer resigned following his appointment as Calzada’s chief executive officer .

Genesis was untraded at 2.6 cents.